SPI Healthcare
3.597,97
PKT
+5,14
PKT
+0,14
%
Werbung
Leider sind zu diesem Wert keine aktuellen Kursdaten verfügbar, die Stammdaten finden Sie im unteren Seitenbereich.
Analysen zu SPI Healthcare-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 04.05.12 | Novartis buy | UBS AG | |
| 04.05.12 | Lonza neutral | Sarasin Research | |
| 04.05.12 | Lonza underperform | Cheuvreux SA | |
| 04.05.12 | Lonza hold | Vontobel Research | |
| 03.05.12 | Novartis neutral | J.P. Morgan Cazenove | |
| 03.05.12 | Novartis hold | Vontobel Research | |
| 30.04.12 | Novartis hold | Vontobel Research | |
| 26.04.12 | Straumann hold | Vontobel Research | |
| 26.04.12 | Novartis outperform | Sanford C. Bernstein and Co., Inc. | |
| 25.04.12 | Novartis kaufen | Hamburger Sparkasse AG (Haspa) | |
| 25.04.12 | Novartis neutral | Exane-BNP Paribas SA | |
| 25.04.12 | Novartis hold | Vontobel Research | |
| 24.04.12 | Novartis buy | WestLB AG | |
| 24.04.12 | Novartis halten | Independent Research GmbH | |
| 24.04.12 | Novartis buy | Sarasin Research | |
| 24.04.12 | Novartis underperform | Cheuvreux SA | |
| 24.04.12 | Novartis hold | Vontobel Research | |
| 23.04.12 | Novartis buy | Nomura | |
| 23.04.12 | Novartis buy | Sarasin Research | |
| 11.04.12 | Novartis buy | UBS AG | |
| 10.04.12 | Novartis neutral | J.P. Morgan Cazenove | |
| 10.04.12 | Sonova kaufen | Die Actien-Börse | |
| 03.04.12 | Lonza neutral | Sarasin Research | |
| 03.04.12 | Novartis neutral | J.P. Morgan Cazenove | |
| 02.04.12 | Novartis buy | Sarasin Research | |
| 27.03.12 | Novartis outperform | Sanford C. Bernstein and Co., Inc. | |
| 22.03.12 | Straumann neutral | Sarasin Research | |
| 21.03.12 | Novartis buy | Deutsche Bank AG | |
| 16.03.12 | Novartis buy | Sarasin Research | |
| 16.03.12 | Novartis neutral | Exane-BNP Paribas SA | |
| 12.03.12 | Basilea Pharmaceutica buy | Sarasin Research | |
| 09.03.12 | Novartis buy | UBS AG | |
| 08.03.12 | Tecan (N) neutral | Sarasin Research | |
| 07.03.12 | Novartis neutral | J.P. Morgan Cazenove | |
| 29.02.12 | Sonova neutral | Sarasin Research | |
| 22.02.12 | Straumann neutral | Sarasin Research | |
| 13.02.12 | Tecan (N) neutral | Sarasin Research | |
| 09.02.12 | Basilea Pharmaceutica buy | Sarasin Research | |
| 07.02.12 | Novartis underperform | Banc of America Securities-Merrill Lynch | |
| 31.01.12 | Novartis neutral | Goldman Sachs Group Inc. |